Delivery of RNA interference

Cell Cycle

Volumn 5, Issue 18, 2006, Pages 2103-2109

  Li, Charles X ^a   Parker, Amy ^a   Menocal, Ellen ^a   Xiang, Shuanglin ^a   Borodyansky, Laura ^a   Fruehauf, Johannes H ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Gene delivery; Gene therapy; RNA interference; Therapeutic RNAi; Transkingdom RNA interference

Indexed keywords

DOUBLE STRANDED RNA; LIPOSOME; NANOPARTICLE; PLASMID DNA; SMALL INTERFERING RNA;

ADENOVIRUS; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; CLINICAL TRIAL; CYSTIC FIBROSIS; DEGENERATIVE DISEASE; DOSE RESPONSE; DRUG ACTIVITY; GENE DELIVERY SYSTEM; GENE FUNCTION; GENE SILENCING; GENE TARGETING; GENETIC CONSERVATION; GENETIC DISORDER; GENETIC REGULATION; HUMAN; HYDRODYNAMICS; IMMUNE DEFICIENCY; IN VIVO STUDY; INFLUENZA; LENTIVIRINAE; LEUKEMIA; NONHUMAN; PROPHYLAXIS; RETROVIRUS; REVIEW; RNA INTERFERENCE; X CHROMOSOME LINKED DISORDER;

MAMMALIA;

EID: 33749681890     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.5.18.3192     Document Type: Review

References (59)

1. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001; 411:494-8.
2. Caplen NJ, Parrish S, Imani F, Fire A, Morgan RA. Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems. Proc Natl Acad Sci USA 2001; 98:9742-7.
3. Theng Ong S, Li F, Du J, Tan YW, Wang S. Hybrid cytomegalovirus Enhancer-H1 promoter-based plasmid and baculovirus vectors mediate effective RNA interference. Hum Gene Ther 2005.
4. Brummelkamp TR, Bernards R, Agami R. Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell 2002; 2:243-247.
5. Kohn DB, Sadelain M, Dunbar C, Bodine D, Kiem HP, Candotti F, Tisdale J, Riviere I, Blau CA, Richard RE. American society of gene therapy (ASGT) ad hoc subcommittee on retroviral-mediated gene transfer to hematopoietic stem cells. Molecular Therapy 2003; 8:180-7.
6. Hacein-Bey-Abina S, von Kalle C, Schmidt M, Le Deist F, Wulffraat N, McIntyre E, Radford I, Villeval JL, Fraser CC, Cavazzana-Calvo M, Fischer A. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2003; 348:255-6.
7. Anson DS. The use of retroviral vectors for gene therapy-what are the risks? A review of retroviral pathogenesis and its relevance to retroviral vector-mediated gene delivery. Genet Vaccines Ther 2004; 2:9.
8. Xia H, Mao Q, Paulson HL, Davidson BL. siRNA-mediated gene silencing in vitro and in vivo. Nat Biotechnol 2002; 20:1006-10.
9. Dittgen T, Nimmerjahn A, Komai S, Licznerski P, Waters J, Margrie TW, Helmchen F, Denk W, Brecht M, Osten P. Lentivirus-based genetic manipulations of cortical neurons and their optical and electrophysiological monitoring in vivo. PNAS 2004; 101:18206-11.
10. Bahi A, Boyer F, Kolira M, Dreyer JL. In vivo gene silencing of CD81 by lentiviral expression of small interference RNAs suppresses cocaine-induced behaviour. Journal of Neurochemistry 2005; 92:1243-55.
11. Singer O, Marr RA, Rockenstein E, Crews L, Coufal NG, Gage FH, Verma IM, Masliah E. Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model. 2005; 8:1343-9.
12. MacKenzie TC, Kobinger GP, Kootstra NA, Radu A, Sena-Esteves M, Bouchard S, Wilson JM, Verma IM, Flake AW. Efficient transduction of liver and muscle after in utero injection of lentiviral vectors with different pseudotypes. Molecular Therapy 2002; 6:349-58.
13. Relph KL, Harrington KJ, Pandha H. Adenoviral strategies for the gene therapy of cancer. Semin Oncol 2005; 32:573-82.
14. Xia H, Mao Q, Eliason SL, Harper SQ, Martins IH, Orr HT, Paulson HL, Yang L, Kotin RM, Davidson BL. RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. Nat Med 2004; 10:816-20.
15. Chen Y, Chen H, Hoffmann A, Cool DR, Diz DI, Chappell MC, Chen A, Morris M. Adenovirus-mediated small-interference RNA for in vivo silencing of angiotensin AT1a receptors in mouse brain. Hypertension 2005, (01.HYP.0000200259.0000201947.bb).
16. Li H, Fu X, Chen Y, Hong Y, Tan Y, Cao H, Wu M, Wang H. Use of adenovirus-delivered siRNA to target oncoprotein p28GANK in hepatocellular carcinoma. Gastroenterology 2005; 128:2029-41.
17. Gurzov EN, Izquierdo M. RNA interference against Hec1 inhibits tumor growth in vivo. 2005; 13:1-7.
18. Osada H, Tatematsu Y, Yatabe Y, Horio Y, Takahashi T. ASH1 gene is a specific therapeutic target for lung cancers with neuroendocrine features. Cancer Res 2005; 65:10680-5.
19. Zhang SZ, Pan FY, Xu JF, Yuan J, Guo SY, Dai G, Xue B, Shen WG, Wen CJ, Zhao DH, Li CJ. Knockdown of c-Met by adenovirus-delivered small interfering RNA inhibits hepatocellular carcinoma growth in vitro and in vivo. Mol Cancer Ther 2005; 4:1577-84.
20. Gou D, Narasaraju T, Chintagari NR, Jin N, Wang P, Liu L. Gene silencing in alveolar type II cells using cell-specific promoter in vitro and in vivo. Nucl Acids Res 2004; 32:e134.
21. Koo SH, Satoh H, Herzig S, Lee CH, Hedrick S, Kulkarni R, Evans RM, Olefsky J, Montminy M. PGC-1 promotes insulin resistance in liver through PPAR-[alpha]-dependent induction of TRB-3. 2004; 10:530-4.
22. Ragozin S, Niemeier A, Laatsch A, Loeffler B, Merkel M, Beisiegel U, Heeren J. Knockdown of hepatic ABCA1 by RNA interference decreases plasma HDL cholesterol levels and influences postprandial lipemia in mice. Arterioscler Thromb Vasc Biol 2005; 25:1433-8.
23. Noureddini SC, Curiel DT. Genetic targeting strategies for adenovirus. Mol Pharm 2005; 2:341-7.
24. Moore MD, McGarvey MJ, Russell RA, Cullen BR, McClure MO. Stable inhibition of hepatitis B virus proteins by small interfering RNA expressed from viral vectors. J Gene Med 2005; 7:918-25.
25. Tomar RS, Matta H, Chaudhary PM. Use of adeno-associated viral vector for delivery of small interfering RNA. Oncogene 2003; 22:5712-5.
26. Babcock AM, Standing D, Bullshields K, Schwartz E, Paden CM, Poulsen DJ. In vivo inhibition of hippocampal Ca2+/calmodulin-dependent protein kinase II by RNA interference. Mol Ther 2005; 11:899-905.
27. Ocker M, Neureiter D, Lueders M, Zopf S, Ganslmayer M, Hahn EG, Herold C, Schuppan D. Variants of bcl-2 specific siRNA for silencing antiapoptotic bcl-2 in pancreatic cancer. Gut 2005; 54:1298-308.
28. Spankuch B, Matthess Y, Knecht R, Zimmer B, Kaufmann M, Strebhardt K. Cancer inhibition in nude mice after systemic application of U6 promoter-driven short hairpin RNAs against PLK1. J Natl Cancer Inst 2004; 96:862-72.
29. Liu F, Song Y, Liu D. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther 1999; 6:1258-66
30. McCaffrey AP, Meuse L, Pham TT, Conklin DS, Hannon GJ, Kay MA. RNA interference in adult mice. Nature 2002; 418:38-9.
31. Lewis DL, Hagstrom JE, Loomis AG, Wolff JA, Herweijer H. Efficient delivery of siRNA for inhibition of gene expression in postnatal mice. Nat Genet 2002; 32:107-8.
32. Kobayashi N, Matsui Y, Kawase A, Hirata K, Miyagishi M, Taira K, Nishikawa M, Takakura Y. Vector-based in vivo RNA interference: Dose- and time-dependent suppression of transgene expression. J Pharmacol Exp Ther 2004; 308:688-93.
33. Zhang G, Gao X, Song YK, Vollmer R, Stolz DB, Gasiorowski JZ, Dean DA, Liu D. Hydroporation as the mechanism of hydrodynamic delivery. Gene Ther 2004; 11:675-82.
34. Tompkins SM, Lo CY, Tumpey TM, Epstein SL. Protection against lethal influenza virus challenge by RNA interference in vivo. Proc Natl Acad Sci USA 2004; 101:8682-6.
35. Braasch DA, Jensen S, Liu Y, Kaur K, Arar K, White MA, Corey DR. RNA interference in mammalian cells by chemically-modified RNA. Biochemistry 2003; 42:7967-5.
36. Elmen J, Thonberg H, Ljungberg K, Frieden M, Westergaard M, Xu Y, Wahren B, Liang Z, Orum H, Koch T, Wahlestedt C. Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality. Nucleic Acids Res 2005; 33:439-47.
37. Crooke ST. Potential roles of antisense technology in cancer chemotherapy. Oncogene 2000; 19:6651-9.
38. Chiu YL, Rana TM. siRNA function in RNAi: A chemical modification analysis. Rna 2003; 9:1034-48.
39. Layzer JM, McCaffrey AP, Tanner AK, Huang Z, Kay MA, Sullenger BA. In vivo activity of nuclease-resistant siRNAs. Rna 2004; 10:766-71.
40. Morrissey DV, Blanchard K, Shaw L, Jensen K, Lockridge JA, Dickinson B, McSwiggen JA, Vargeese C, Bowman K, Shaffer CS, Polisky BA, Zinnen S. Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication. Hepatology 2005; 41:1349-56.
41. Prakash TP, Allerson CR, Dande P, Vickers TA, Sioufi N, Jarres R, Baker BF, Swayze EE, Griffey RH, Bhat B. Positional effect of chemical modifications on short interference RNA activity in mammalian cells. J Med Chem 2005; 48:4247-53.
42. Flynn MA, Casey DG, Todryk SM, Mahon BP. Efficient delivery of small interfering RNA for inhibition of IL-12p40 expression in vivo. J Inflamm (Lond) 2004; 1:4.
43. Sorensen DR, Leirdal M, Sioud M. Gene silencing by systemic delivery of synthetic siRNAs in adult mice. J Mol Biol 2003; 327:761-6.
44. Miyawaki-Shimizu K, Predescu D, Shimizu J, Broman M, Predescu S, Malik AB. siRNA-induced caveolin-1 knockdown in mice increases lung vascular permeability via the junctional pathway. Am J Physiol Lung Cell Mol Physiol 2006; L405-13.
45. Landen Jr CN, Chavez-Reyes A, Bucana C, Schmandt R, Deavers MT, Lopez-Berestein G, Sood AK. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res 2005; 65:6910-8.
46. Ge Q, Filip L, Bai A, Nguyen T, Eisen HN, Chen J. Inhibition of influenza virus production in virus-infected mice by RNA interference. Proc Natl Acad Sci USA 2004; 101:8676-81.
47. Urban-Klein B, Werth S, Abuharbeid S, Czubayko F, Aigner A. RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther 2005; 12:461-6.
48. Morrissey DV, Lockridge JA, Shaw L, Blanchard K, Jensen K, Breen W, Hartsough K, Machemer L, Radka S, Jadhav V, Vaish N, Zinnen S, Vargeese C, Bowman K, Shaffer CS, Jeffs LB, Judge A, MacLachlan I, Polisky B. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol 2005; 23:1002-7.
49. Zhang Y, Boado RJ, Pardridge WM. In vivo knockdown of gene expression in brain cancer with intravenous RNAi in adult rats. J Gene Med 2003; 5:1039-45.
50. Schiffelers RM, Ansari A, Xu J, Zhou Q, Tang Q, Storm G, Molema G, Lu PY, Scaria PV, Woodle MC. Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res 2004; 32:e149.
51. Zitzmann S, Ehemann V, Schwab M. Arginine-glycine-aspartic acid (RGD)-peptide binds to both tumor and tumor-endothelial cells in vivo. Cancer Res 2002; 62:5139-43.
52. Song E, Zhu P, Lee SK, Chowdhury D, Kussman S, Dykxhoorn DM, Feng Y, Palliser D, Weiner DB, Shankar P, Marasco WA, Lieberman J. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. 2005; 23:709-17.
53. Schaffner W. Direct transfer of cloned genes from bacteria to mammalian cells. Proc Natl Acad Sci USA 1980; 77:2163-7.
54. Courvalin P, Goussard S, Grillot-Courvalin C. Gene transfer from bacteria to mammalian cells. C R Acad Sci III 1995; 318:1207-12.
55. Sizemore DR, Branstrom AA, Sadoff JC. Attenuated Shigella as a DNA delivery vehicle for DNA-mediated immunization. Science 1995; 270:299-302.
56. Hense M, Domann E, Krusch S, Wachholz P, Dittmar KE, Rohde M, Wehland J, Chakraborty T, Weiss S. Eukaryotic expression plasmid transfer from the intracellular bacterium listeria monocytogenes to host cells. Cell Microbiol 2001; 3:599-609.
57. Palffy R, Gardlik R, Hodosy J, Behuliak M, Resko P, Radvansky J, Celec P. Bacteria in gene therapy: Bactofection versus alternative gene therapy. 2005; 13:101-5.
58. Xiang S, Fruehauf J, Li CJ. Short hairpin RNA expressing bacteria elicit RNA interference in mammals. Nat Biotechnology 2006; 24:697-702.
59. Zhao HF, L'Abbe D, Jolicoeur N, Wu M, Li Z, Yu Z, Shen SH. High-throughput screening of effective siRNAs from RNAi libraries delivered via bacterial invasion. Nat Methods 2005; 2:967-73.